Page last updated: 2024-08-26

cb 10375 and Vomiting

cb 10375 has been researched along with Vomiting in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abel, G; Ashley, SE; Cairnduff, F; Calvert, AH; Evans, BD; Graham, MA; Gumbrell, LA; Judson, IR; Rutty, CJ; Wilman, DE1
Bermudez, J; Boyle, EA; Miner, WD; Sanger, GJ1

Trials

1 trial(s) available for cb 10375 and Vomiting

ArticleYear
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Cancer research, 1989, Oct-01, Volume: 49, Issue:19

    Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Triazines; Vomiting

1989

Other Studies

1 other study(ies) available for cb 10375 and Vomiting

ArticleYear
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
    British journal of cancer, 1988, Volume: 58, Issue:5

    Topics: Animals; Apomorphine; Cisplatin; Cyclophosphamide; Dogs; Doxorubicin; Ferrets; Granisetron; Indazoles; Male; Pyrazoles; Triazines; Vomiting; Whole-Body Irradiation

1988